Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1757-1763

  Chae, Yee Soo ^a   Shin, Hocheol ^a   Sohn, Sang Kyun ^a   Lee, Soo Jung ^a   Moon, Joon Ho ^a   Kang, Byung Woog ^a   Kim, Jong Gwang ^a   Yang, Deok Hwan ^b   Lee, Je Jung ^b   Park, Tae In ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Chonnam National University Research Institute of Medical Sciences   (South Korea)

Author keywords

absolute lymphocyte count; Diffuse large B cell lymphoma; prognostic marker; rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TUMOR MARKER; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; VINCRISTINE; YOUNG ADULT;

EID: 84864982321     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.670231     Document Type: Article

References (28)

1. Coiffi er B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared wiThCHOP alone in elderly patients wiThdiff use large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
2. F eugier P, Van Hoof A, Sebban C et al. Long-Term results of the R-CHOP study in the treatment of elderly patients wiThdiff use large B-cell lymphoma: A study by the Grouped Etude des Lymphomes de l Adulte. J Clin Oncol 2005;23:4117-4126.
3. P freundschuh M, Trumper L, Osterborg A et a l. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients wiThgood-prognosis diff use large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
4. S ehn LH, Donaldson J, Chhanabhai M, et a l. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diff use large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033.
5. S ehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients wiThdiff use large B-cell lymphoma treated wiThR-CHOP. Blood 2007;109:1857-1861.
6. Chae YS, Kim JG, Sohn SK et al. Lymphotoxin alfa and receptorinteracting protein kinase 1 gene polymorphisms may correlate wiThprognosis in patients wiThdiff use large B cell lymphoma treated wiThR-CHOP. Cancer Chemother Pharmacol 2010;65:571-577.
7. Barrans S, Crouch S, SmithA, et al. Rearrangement of MYC is associated wiThpoor prognosis in patients wiThdiff use large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28: 3360-3365.
8. Y oon DH, Choi DR, Ahn HJ, et a l. Ki-67 expression as a prognostic factor in diff use large B-cell lymphoma patients treated wiThrituximab plus CHOP. Eur J Haematol 2010;85:149-157.
9. Talaulikar D, Choudhury A, Shadbolt B, et al. Lymphocytopenia as prognostic marker for diff use large B cell lymphomas. Leuk Lymphoma 2008;49:959-964.
10. C ox MC, Nofroni I, Ruco L et a l. Low absolute lymphocyte count is a poor prognostic factor in diff use-large-B-cell-lymphoma. Leuk Lymphoma 2008;49:1745-1751.
11. O ki Y, Yamamoto K, Kato H, et al. Low absolute lymphocyte count is a poor prognostic marker in patients wiThdiff use large B-cell lymphoma and suggests patients survival benefi t from rituximab. Eur J Haematol 2008;81:448-453.
12. Song MK, Chung JS, Seol YM, et al. Infl uence of low absolute lymphocyte count of patients wiThnongerminal center type diff use large B-cell lymphoma wiThR-CHOP therapy. Ann Oncol 2010;21: 140-144.
13. Cheson BD, Pfi stner B, Juweid ME, et a l. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
14. Zhou T, Jiang Y, Yao J. [Expression of adhesion molecules on lymphocyte in patients wiThsystemic lupus erythematosus]. Zhonghua Nei Ke Za Zhi 1995;34:545-547.
15. Kim H, Sohn HJ, Kim SE, et a l. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;34:43-49.
16. K im H, Sohn HJ, Kim S, et al. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1037-1042.
17. Joao C, Porrata LF, Inwards DJ, et a l. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant 2006;37: 865-871.
18. B oulassel MR, Herr AL, deB Edwardes MD, et al. Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated wiThbetter survival in younger patients wiThlymphoproliferative disorders. Hematology 2006;11: 165-170.
19. Behl D, Porrata LF, Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20:29-34.
20. P orrata LF, Inwards DJ, Ansell SM, et a l. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: A prospective study. Biol Blood Marrow Transplant 2008;14:807-816.
21. P orrata LF, Ingle JN, Litzow MR, et al. Prolonged survival associated wiThearly lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients wiThmetastatic breast cancer. Bone Marrow Transplant 2001;28:865-871.
22. K im DH, Baek JH, Chae YS, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diff use large B-cell lymphoma. Leukemia 2007;21:2227-2230.
23. P aiva M, Marques H, Martins A, et al. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet 2008;183:35-40.
24. H atjiharissi E, Hansen M, Santos DD, et al. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007;7:286-290.
25. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients wiThfollicular lymphoma. J Clin Oncol 2003;21: 3940-3947.
26. Cartron G, Dacheux L, Salles G, et a l. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-758.
27. E dwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-211.
28. M cLaughlin P, Grillo-Lopez AJ, Link BK, et a l. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.